Adam S. Fleisher spends much of his time researching Alzheimer's disease, Dementia, Pathology, Internal medicine and Neuroimaging. He interconnects Biomarker, Cognition, Neuroscience and Clinical trial in the investigation of issues within Alzheimer's disease. In his research on the topic of Dementia, Cardiology, Autopsy and Florbetaben is strongly related with Positron emission tomography.
His primary area of study in Pathology is in the field of Presenilin. The study incorporates disciplines such as Gastroenterology and Surgery in addition to Internal medicine. His research integrates issues of Alzheimer's Disease Neuroimaging Initiative, Magnetic resonance imaging and Brain mapping in his study of Neuroimaging.
Adam S. Fleisher focuses on Alzheimer's disease, Internal medicine, Disease, Neuroscience and Dementia. Pathology covers Adam S. Fleisher research in Alzheimer's disease. His Pathology study combines topics in areas such as Young adult and Positron emission tomography.
His Internal medicine study integrates concerns from other disciplines, such as Endocrinology, Oncology, Brain mapping and Cardiology. He has researched Disease in several fields, including Clinical trial, Beta and Gerontology. His work investigates the relationship between Dementia and topics such as Alternative medicine that intersect with problems in Pediatrics.
His primary areas of study are Alzheimer's disease, Cognitive decline, Neuroscience, Pathology and Dementia. The Alzheimer's disease portion of his research involves studies in Internal medicine and Disease. His Cognitive decline research is multidisciplinary, relying on both Psychiatry, Effects of sleep deprivation on cognitive performance and Pediatrics.
His Pathology research includes themes of Biomarker and White matter. His research investigates the connection with Dementia and areas like Cognitive impairment which intersect with concerns in Brain region, Diagnostic marker and Middle frontal gyrus. His studies in Neuroimaging integrate themes in fields like Alzheimer's Disease Neuroimaging Initiative, Magnetic resonance imaging, Artificial intelligence and Pattern recognition.
Adam S. Fleisher mainly investigates Alzheimer's disease, Cognitive decline, Pathology, Psychiatry and Alzheimer's Disease Neuroimaging Initiative. His Alzheimer's disease study combines topics from a wide range of disciplines, such as Differential diagnosis and Dementia. His work carried out in the field of Dementia brings together such families of science as Clinical endpoint, Apolipoprotein E, Physical medicine and rehabilitation and Cognitive test.
His Cognitive decline research focuses on Cognition and how it relates to Severity of illness, Cohort, Neuroimaging and Clinical trial. His Pathology research is multidisciplinary, incorporating perspectives in Biomarker, Internal medicine and Precuneus. The Alzheimer's Disease Neuroimaging Initiative study combines topics in areas such as Pathological, Brain mapping and Right entorhinal cortex.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods.
Clifford R. Jack;Matt A. Bernstein;Nick C. Fox;Paul Thompson.
Journal of Magnetic Resonance Imaging (2008)
Use of Florbetapir-PET for Imaging β-Amyloid Pathology
Christopher M. Clark;Julie A. Schneider;Barry J. Bedell;Thomas G. Beach.
Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis
Y. Iturria-Medina;R. C. Sotero;P. J. Toussaint;J. M. Mateos-Pérez.
Nature Communications (2016)
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study
Christopher M Clark;Michael J Pontecorvo;Thomas G Beach;Barry J Bedell.
Lancet Neurology (2012)
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
Eric M Reiman;Yakeel T Quiroz;Yakeel T Quiroz;Adam S Fleisher;Kewei Chen.
Lancet Neurology (2012)
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.
Rik Ossenkoppele;Willemijn J Jansen;Gil D Rabinovici;Dirk L Knol.
Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease
Adam S. Fleisher;Rema Raman;Eric R. Siemers;Lida Becerra.
JAMA Neurology (2008)
Alzheimer’s Prevention Initiative: A Plan to Accelerate the Evaluation of Presymptomatic Treatments
Eric M. Reiman;Jessica B.S. Langbaum;Adam S. Fleisher;Richard J. Caselli.
Journal of Alzheimer's Disease (2011)
Using Positron Emission Tomography and Florbetapir F 18 to Image Cortical Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer Disease
Adam S. Fleisher;Kewei Chen;Xiaofen Liu;Auttawut Roontiva.
JAMA Neurology (2011)
Sex, Apolipoprotein E ε4 Status, and Hippocampal Volume in Mild Cognitive Impairment
Adam Fleisher;Michael Grundman;Clifford R. Jack;Ronald C. Petersen.
JAMA Neurology (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: